TrialBreast cancer research and treatment2019

Pathologic complete response and outcomes by intrinsic subtypes in NSABP B-41, a randomized neoadjuvant trial of chemotherapy with trastuzumab, lapatinib, or the combination.

Sandra M Swain et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.